OncoTherapy Science (4564) AI Stock Analysis

• Market Cap: €8.23B
• Dividend Yield: N/A
• Average Volume (3M): 6.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: 22.93%
• EPS Growth: 47.73%
• Country: JP
• Employees: 54
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -3.16
• Shares Outstanding: 304,643,700
• 10 Day Avg. Volume: 14,901,810
• 30 Day Avg. Volume: 6,917,313
• PEG Ratio: 0.14
• Price to Book (P/B): 10.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ¥31.00 ▲(10.71%Upside)

The overall stock score is primarily influenced by the company's poor financial performance, marked by persistent losses and negative cash flows. Technical analysis shows some positive momentum, but the overbought indicators suggest caution. Valuation metrics are negative, reflecting the company's current lack of profitability and dividend yield.

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science, Inc. (4564) is a biotechnology company focused on the development and commercialization of innovative cancer therapeutics. The company's core products include biologics and small-molecule drugs designed to target and inhibit cancer cell growth. Operating within the pharmaceutical and biotechnology sectors, OncoTherapy Science aims to advance cancer treatment through cutting-edge research and development initiatives.

How the Company Makes Money

OncoTherapy Science, Inc. generates revenue primarily through the development and commercialization of its proprietary cancer therapeutics. The company makes money by licensing its drug candidates to pharmaceutical companies and entering into strategic partnerships for co-development and commercialization. These collaborations often involve upfront payments, milestone payments, and royalties on sales of successfully developed drugs. Additionally, OncoTherapy Science may receive research grants and funding to support its R&D activities. The company's revenue model relies heavily on the successful progression of its drug candidates through clinical trials and eventual market approval.

OncoTherapy Science Financial Statement Overview

Summary

OncoTherapy Science faces significant financial challenges, with persistent losses and cash flow issues. While the balance sheet shows some equity strength, the overall financial performance suggests instability, common in the biotech industry due to high R&D expenses and long timelines to profitability. The company needs strategic financial management to navigate these challenges and improve financial health.

Income Statement

The company has experienced significant challenges in profitability, with consistently negative net and gross profit margins. Revenue growth is erratic, with fluctuations in revenue suggesting instability. EBIT and EBITDA margins have been consistently negative, indicating operational inefficiencies. Overall, the income statement reflects a struggling financial performance, typical in high-risk biotech ventures.

Balance Sheet

The balance sheet shows a relatively high equity ratio, supported by substantial stockholders' equity compared to total assets. However, the company carries significant liabilities, resulting in a moderate debt-to-equity ratio. The consistent decline in total assets and stockholders' equity over the years indicates potential risk. The company's ability to manage liabilities is crucial, given its negative equity growth trend.

Cash Flow

The cash flow statements reveal persistent negative free cash flow and operating cash flow, which are concerning for future liquidity. The company has relied heavily on financing activities to sustain operations, indicating potential challenges in sustaining cash flows from core operations. There is a lack of positive cash flow generation, which poses a risk to financial stability.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	707.11M	750.05M	610.12M	1.13B	1.15B	332.48M
Gross Profit	-207.51M	-12.76M	-177.72M	41.69M	113.91M	19.54M
EBITDA	-587.20M	-811.92M	-1.29B	-1.09B	-2.04B	-1.59B
Net Income	-1.02B	-815.28M	-1.29B	-1.12B	-2.57B	-1.56B
Balance Sheet
Total Assets	1.23B	1.16B	867.27M	1.51B	2.69B	3.37B
Cash, Cash Equivalents and Short-Term Investments	945.00M	833.88M	527.66M	1.12B	1.84B	2.90B
Total Debt	0.00	51.07M	106.85M	0.00	0.00	0.00
Total Liabilities	404.00M	426.09M	513.61M	656.27M	704.97M	291.28M
Stockholders Equity	828.00M	729.11M	353.67M	855.17M	1.98B	3.08B
Cash Flow
Free Cash Flow	0.00	-815.30M	-1.23B	-800.29M	-2.53B	-1.81B
Operating Cash Flow	0.00	-815.02M	-1.23B	-794.90M	-2.07B	-1.76B
Investing Cash Flow	0.00	-279.00K	-33.35M	-20.32M	-467.93M	-52.23M
Financing Cash Flow	0.00	1.12B	671.37M	95.95M	1.48B	0.00

OncoTherapy Science Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Positive. The current price of 28 is above the 20-day moving average (MA) of 24.40, above the 50-day MA of 23.60, and above the 200-day MA of 27.93, indicating a bullish trend. The MACD of 1.43 indicates Negative momentum. The RSI at 59.90 is Neutral, neither overbought nor oversold. The STOCH value of 36.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4564.

OncoTherapy Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
4583	48 Neutral	¥9.66B	―		―	14.41%	27.42%
4564	47 Neutral	€8.23B	―	-148.36%	―	22.93%	47.73%
4588	45 Neutral	¥14.81B	―		―	11.93%	15.04%
4881	38 Underperform	¥4.26B	―		―	1056.04%	21.63%
4593	37 Underperform	¥44.28B	―		―	374.19%	35.53%
4598	28 Underperform	¥7.64B	―		―	―	-11.46%